Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ongoing progress in BRAF-mutated non-small cell lung cancer.

Clinical advances in hematology & oncology : H&O - 1 Nov 2022

Abdayem Pamela, Planchard David

Abstract excerpt

Activating BRAF mutations are detected in 1.5% to 4.5% of patients with non-small cell lung cancer (NSCLC). These mutations involve the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway, and affect proliferation, differentiation, transcriptional regulation, and survival of cancer cells. Today, the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib is the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Oximes
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Source

Identifiers

PMID: 36331404

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ongoing progress in BRAF-mutated non-small cell lung cancer.PMID 36331404Read ↗

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.Semantic proximity Read ↗

Advances in anti-BRAF therapies for lung cancer.Semantic proximity Read ↗

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Semantic proximity Read ↗

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Semantic proximity Read ↗

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.Semantic proximity Read ↗

Dabrafenib and trametinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.Semantic proximity Read ↗

BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

[Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].Semantic proximity Read ↗

BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.